<DOC>
	<DOC>NCT02134964</DOC>
	<brief_summary>This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will be randomized in a ratio of 5 active to 1 placebo.</brief_summary>
	<brief_title>Phase 1 Safety and PK Study of OLT1177 Capsules</brief_title>
	<detailed_description />
	<criteria>Age 18 to 60 years old, inclusive In good health as determined by the Investigator based on subject's medical history, ECG and physical examination at Baseline and safety laboratory tests (chemistry, hematology, coagulation and urinalysis) at Screening Normal blood pressure of 130/85 mmHg or lower Ability to provide written, informed consent prior to initiation of any studyrelated procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential who: 1. Are or intend to become pregnant (including use of fertility drugs) during the study 2. Are nursing 3. Are not using an acceptable, highly effective method of contraception until all followup procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonalbased birth control is being used, subject or subject's sexual partner(s) must be on a stabledose for â‰¥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the study.) Use of any drug treatment at the time of the study (with the exception of 81 mg aspirin and prescription oral or systemic contraceptives) Taking any prescription medications (other than oral or systemic contraceptives) within 14 days prior to administration of investigational drug or taking any overthecounter products (including natural food supplements, vitamins, garlic as a supplement) within 14 days prior to administration of investigational drug, except for topical products without systemic absorption Use of NSAIDs or other prescription pain medication, more than once or twice a week, especially if taken for chronic or frequently recurring headache Active infection within 3 days of the Baseline visit History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV) Diagnosed with any form of internal cancer within the past 5 years Any other medical conditions, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing any protocol requirements History of anaphylactic reactions to any systemic or topical compounds Have donated plasma (500 mL) within 7 days prior to drug administration Have donated or lost whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows: 50 mL to 499 mL of whole blood within 30 days, or more than 499 mL of whole blood within 56 days prior to drug administration Is a user of any nicotine products (including chewing tobacco, snuff and/or ecigarettes) Is not willing to restrict food or beverage including: alcohol, caffeine, poppy seeds, xanthine derivatives or xanthinerelated compounds, energy drinks, natural health products, grapefruit juice, pomelo, Seville orange and marmalade use during the study as specified in Section 7.1.5 Is lactose intolerant Is unable or unwilling to consume products containing bovine byproducts Is unable to adhere to or understand the requirements of the protocol If continuing on to Part B, subject is unable or unwilling to ingest the full studyprovided highfat breakfast within 30 minutes Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30day period prior to the Baseline visit Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT117701, Study OLT117702 or Study OLT117703</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Randomized</keyword>
	<keyword>Healthy volunteers</keyword>
	<keyword>OLT1177</keyword>
	<keyword>Olatec</keyword>
</DOC>